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Simple Summary: It is well known that different cancer predisposition syndromes are associated
with characteristic WT-features. The following findings from our retrospective analysis of patients
with nephroblastoma treated according to the SIOP/GPOH trials between 1989 and 2017 are rele-
vant: (1) The outcome of patients with a cancer predisposition syndrome is not always favorable
despite early diagnosis, small tumors and less metastatic disease. This finding is partly depending
on complications related to the underlying syndrome. (2) Predisposition syndromes seem to be
underdiagnosed as several clinical and pathological features of Wilms tumor being clearly linked to a
cancer predisposition syndrome did not lead to genetic counseling before and after WT diagnosis. As
a conclusion, in children with a nephroblastoma and specific clinical and pathological features that
are in line with a nephroblastoma cancer predisposition syndrome such a syndrome should always
be considered and ruled out if unknown at the time of tumor diagnosis.
Abstract: (1) Background: about 10% of Wilms Tumor (WT) patients have a malformation or cancer
predisposition syndrome (CPS) with causative germline genetic or epigenetic variants. Knowledge
on CPS is essential for genetic counselling. (2) Methods: this retrospective analysis focused on
2927 consecutive patients with WTs registered between 1989 and 2017 in the SIOP/GPOH studies.
(3) Results: Genitourinary malformations (GU, N = 66, 2.3%), Beckwith-Wiedemann spectrum
(BWS, N = 32, 1.1%), isolated hemihypertrophy (IHH, N = 29, 1.0%), Denys-Drash syndrome (DDS,
N = 24, 0.8%) and WAGR syndrome (N = 20, 0.7%) were reported most frequently. Compared to
others, these patients were younger at WT diagnosis (median age 24.5 months vs. 39.0 months),
had smaller tumors (349.4 mL vs. 487.5 mL), less often metastasis (8.2% vs. 18%), but more often
nephroblastomatosis (12.9% vs. 1.9%). WT with IHH was associated with blastemal WT and DDS
with stromal subtype. Bilateral WTs were common in WAGR (30%), DDS (29%) and BWS (31%).
Chemotherapy induced reduction in tumor volume was poor in DDS (0.4% increase) and favorable
in BWS (86.9% reduction). The event-free survival (EFS) of patients with BWS was significantly
(p = 0.002) worse than in others. (4) Conclusions: CPS should be considered in WTs with specific
clinical features resulting in referral to a geneticist. Their outcome was not always favorable.
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1. Introduction
Nephroblastoma or Wilms tumor (WT), the most common kidney tumor in child-
hood [1], can be cured in more than 90% today [2–4]. According to SIOP clinical studies
and trials patients are diagnosed by imaging studies alone and preoperatively treated with
AV (actinomycin and vincristine for 4 weeks) with localized or with (AV plus doxorubicin
for 6 weeks) with metastatic tumors. During the registration process of patients, data on
the kind of a cancer predisposition syndromes (CPS) or a malformation are provided by
the treating hospital without further specifying malformations. In addition, participation
in a surveillance protocol before the diagnosis in case of a CPS is registered in the database.
With 8 to 17% overall and up to 24% in bilateral WTs it has one of the highest associa-
tion rates with congenital anomalies of all childhood cancers [5,6]. Such malformations
and CPS related to the development of WTs are characterized by genetic or epigenetic alter-
ations. For example, the WAGR syndrome, is clinically defined by a variable occurrence
of WT in combination with aniridia, genitourinary malformations and a range of devel-
opmental delays [7–9]. It is caused by chromosome 11p13 deletions, including WT1 and
neighboring genes, whereas Denys-Drash syndrome (DDS) is due to a dominant-negative
WT1 mutation. DDS is characterized by the triad of WT, nephropathy and, if applicable,
male pseudohermaphroditism [10–12]. In addition, genitourinary malformations (GU)
have been linked to WT1 mutations [13,14]. Isolated hemihypertrophy (IHH) [15,16] and
the Beckwith-Wiedemann spectrum (BWS) are overgrowth syndromes with elevated risk
to develop WT. BWS shows a high variability of macroglossia, abdominal wall defects, vis-
ceromegaly, gigantism and hypoglycaemia caused by genetic and epigenetic alterations at
11p15.3 [12,17,18]. Other WT associated syndromes such as Perlman syndrome or Simpson-
Golabi-Behmel syndrome are much rarer and have a different genetic background. In this
paper we focus on the five most frequent WT malformations or CPS, namely WAGR, DDS,
GU, IHH and BWS, to compare their clinical, pathological and outcome data with data
from WTs without a known CPS.
2. Materials and Methods
We conducted a retrospective investigation on data of 2927 patients with WT and/or
nephroblastomatosis from Germany, Austria and Switzerland enrolled in the SIOP/GPOH
9, 93-01 and 2001 studies between 1989 and 2017. Details of their treatment protocols have
been reviewed previously [19]. Ethical approval was obtained from the Ärztekammer
des Saarlandes (No: 136/01 from 20 September 2002 and, 248/13 from 13 January 2014).
All parents or legal guardians of the affected children gave informed consent for study
participation.
Pseudonymized data of all patients were stored in a central and encrypted SQL
database. All patients identified in the database with a clinically documented malformation
or CPS were reviewed by NW and NG, and details on these patients—including presen-
tation, treatments and outcome—were collected from the SIOP-RTSG/GPOH database
and, retrospectively, from status report forms, radiology, pathology and surgery reports,
progress letters and telephone notes available at the data center. The identification of
patients with malformations or CPS was based solely on clinical data provided by the
registration CRF where associated congenital malformations or a syndrome were asked
specifically for Aniridia, WAGR, genitourinary malformations, Denys Drash syndrome,
BWS, IHH, Perlman syndrome. Free text could specify other malformations or syndromes
that are not listed. This information is based on clinical characteristics. No information is
provided if the syndrome was confirmed by genetic analysis. Patients with WAGR were
also included in the paper by Hol et al. [8]. Tumor volume was calculated from imaging
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studies using the ellipsoid formula in those patients were CT or MRI of the tumor was
available. Nephroblastomatosis was based on reference histology defined as multiple or
diffuse nephrogenic rests but not further specified as perilobar, intralobar or both, as this
information was not available for all patients with nephroblastomatosis. For statistical
analysis all data were anonymized. IBM SPSS Statistics, version 25 and 27, was used for
descriptive analyses (histograms, boxplots, pie charts, frequency charts and bar charts)
and statistical comparisons (T-test for independent samples, Levene test, Chi-square test,
multivariate analysis and Kaplan-Meier survival curves with Log Rank). p-values below
0.05 were considered as statistically significant. Overall survival (OS) included the time
period between diagnosis and death of any reason, and event free survival (EFS) between
diagnosis and any event, including recurrence of WT or nephroblastomatosis, death or loss
to follow up.
3. Results
3.1. Characteristics of Study Population
An underlying malformation or syndrome was recorded in 198 out of all 2927 (6.8%)
patients (Table 1). Bilateral disease occurred in 253 (8.6%) of patients and 29 patients
with CPS or malformation were included in a surveillance programm before diagnosis
of a WT and/or nephroblastomatosis. In 137/2927 (4.6%) patients nephroblastomatosis
was diagnosed, either isolated (73; 2.4%) or in conjunction with WT (64; 2.1%). This
investigation highlights specifically a sub-cohort of 171 patients, who presented with
one of the five most frequent malformations or syndromes (Table 1), that is GU (N = 66),
BWS (N = 32), IHH (N = 29), DDS (N = 24) and WAGR syndrome (N = 20). In addition,
27 patients were diagnosed with a variety of other malformations or syndromes (Table S1).
Interestingly, there was no increase of the percentage of patients with CPS or GU over time.
Up to year 2000, 54.9% of CPS or GU were diagnosed and 45.1% in the following years.
Table 1. Frequency of malformations and CPS in WT/nephroblastomatosis (NBL).
Frequency
All Patients with WT and/or NBL Only Bilateral WT and/or NBL Only Screened Patients withCPS/Malformation and WT and/or NBL
All WT 2927 - 100% 253 8.6% ** 29 *** **** **
WAGR 20
∑ = 171
0.7% 6 2.4% 30.0% 8 27.6% 40.0%
GU 66 2.3% 8 3.2% 12.1% 1 3.4% 1.5%
DDS 24 0.8% 7 2.8% 29.2% 3 10.3% 12.5%
BWS 32 1.1% 10 4.0% 31.3% 10 34.5% 31.3%
IHH 29 1.0% 4 1.6% 13.8% 4 13.8% 13.8%
Other * 27 - 0.9% 7 2.8% 25.9% 3 10.3% 11.1%
All 198 - 6.8% 42 16.6% 21.2% 29 100% 14.6%
* see Table S1; ** % related to the specific malformations or CPS, *** screening in 29 of 198 patients with malformations or CPS, **** % related
to the 29 screened patients with malformations or CPS. WT: Wilms tumor; CPS: cancer predisposition syndrome; NBL: nephroblastomatosis.
3.2. Ultrasound Surveillance Every 3 Months
Altogether 29 (14.6%) patients had been screened by ultrasound every 3 months after
the diagnosis of a CPS. The highest screening frequency resulting in the diagnosis of
WT/nephroblastomatosis was reported in patients with WAGR (40%) and BWS (31.3%).
(Table 1). No data were available on why not all children with an underlying syndrome
were included in a screening program.
3.3. Gender Distribution and Age at Diagnosis of WT/Nephroblastomatosis
Gender distribution in the whole cohort of patients with syndrome-associated WT is
similar to the total group of patients with WT/nephroblastomatosis with a predominance
of females (51.4% females vs. 48.1% males, 0.5% gender not known) with the exception
of GU cases. 43 males (3.2% of 1353) and 23 females (1.5% of 1562) were affected by GU
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malformations. In DDS a slight male predominance has also been observed, but without
statistical significance.
With a median age of 24.5 months (mean: 40.3 +/− 36.7 months), patients with
associated malformations or syndromes were significantly (t-test: p < 0.001) younger at
diagnosis of WT/nephroblastomatosis than patients without a malformation or syndrome
(median age: 39.0 months; mean age: 50.0 +/− 51.6 months). Patients with WAGR (median
age: 21 months; mean age: 23.8 +/− 9.0 months) and DDS (median age: 16.0 months; mean
age: 16.7 +/− 12.2 months) were even significantly younger at diagnosis than patients
with other syndromes (Figure 1).
Figure 1. Age of WT/nephroblastomatosis at diagnosis of syndrome-associated WTs displayed as a boxplot (The line in
the bar shows the median, the left end of the bar the lower quartile and the upper end of the bar the upper quartile, the
horizontal line ranges from the minimum to the maximum of data with dots and stars as outliers). DDS and WAGR show a
significant lower age at diagnosis compared to all other syndromes (p < =0.001). In 3 patients with CPS WT was diagnosed
beyond 10 years of age (IHH (173 months), GU (146 months, 325 months)) and in 143 WT without a syndrome beyond
120 months, the last one at 628 months (data not shown). WT: Wilms tumor; GU: Genitourinary malformations; BWS:
Beckwith-Wiedemann spectrum; IHH: isolated hemihypertrophy; DDS: Denys-Drash syndrome; WAGR: Wilms tumor,
aniridia, genitourinary abnormalities, range of developmental delays.
3.4. Bilaterality
There was a statistically significant higher incidence of bilaterality in patients with
(21.2%) than without a syndrome (7.4%) (p < 0.05), especially in patients with BWS (31.3%),
WAGR (30.0%) and DDS (29.2%) compared to other patients with WT and/or nephroblas-
tomatosis (Table 1).
3.5. Metastatic Disease in Patients with CPS or Malformations
In the whole group of patients 18% (529/2927) had a primary metastatic disease (stage
IV) while in the cohort of patients with the five most common WT associated syndromes,
primary metastatic disease was observed in less than 8.0% (14/171) (p < 0.001) with the
exception of IHH (17.2%, p = 0.014) (see Table S3).
3.6. Histology
According to the SIOP studies and trials histology of WT is classified in low, inter-
mediate and high risk, depending on the availability of diffuse anaplasia, the percentage
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of necrosis and the percentage of blastema, epithel and stroma in the vital tumor part
after preoperative chemotherapy. Blastemal type WT and diffuse anaplasia are high risk
tumors. Stromal type is mainly associated with WT1 mutations and is not responding on
preoperative chemotherapy despite the fact that patients with stromal type WT have an
excellent outcome in case of a localized tumor. The histological risk group together with
the local and overall stage defines postoperative treatment. In addition, information about
nephrogenic rests or nephroblastomatosis are provided. Mixed type, an intermediate risk
tumor, is, with the exception of WAGR syndrome, the most common histological subtype
for all WTs with or without syndromes. Patients with CPS are significantly more likely to
have isolated nephroblastomatosis. In particular, a significantly increased proportion of
isolated nephroblastomatosis is observed in WAGR, BWS and IHH (Table 2).
Table 2. Association between nephroblastomatosis (NBL) and CPS or malformation in the whole cohort of patients and
bilateral disease; * chi-square p ≤ 0.001. WT: Wilms tumor; CPS: cancer predisposition syndrome; NBL: nephroblastomatosis;
GU: Genitourinary malformations; BWS: Beckwith-Wiedemann spectrum; IHH: isolated hemihypertrophy; DDS: Denys-
Drash syndrome; WAGR: Wilms tumor, aniridia, genitourinary abnormalities, range of developmental delays.
Isolated NBL WT + NBL WT Only Total
Total 73 2.5% 64 2.2% 2790 95.3% 2927 100%
Bilateral disease 31 42.5% 61 95.3% 161 5.8% 253 100%
Patients with CPS or GU 22 * 12.9% * 11 12.9% 138 80.7% 171 100%
Patients without CPS or GU 51 1.9% 53 1.9% 2652 96.2% 2756 100%
WAGR 7 * 35.0% * 2 10.0% 11 55.0% 20 100%
BWS 7 * 21.9% * 3 9.4% 22 68.8% 32 100%
IHH 5 * 17.2% * 0 0.0% 24 82.8% 29 100%
DDS 1 4.2% 2 8.3% 21 87.5% 24 100%
GU 2 3.0% 4 6.1% 60 90.9% 66 100%
There was also a statistically significant association of IHH with the blastemal sub-
type after preoperative chemotherapy (p = 0.040) and of DDS with stromal subtype
(p < 0.001) (Table 3).
Table 3. Association between histological subtypes and CPS or malformation; * chi-square: p ≤ 0.040.
WT: Wilms tumor; GU: Genitourinary malformations; BWS: Beckwith-Wiedemann spectrum; IHH:
isolated hemihypertrophy; DDS: Denys-Drash syndrome; WAGR: Wilms tumor, aniridia, genitouri-
nary abnormalities, range of developmental delays.
Stromal Subtype Blastemal Subtype afterPreoperative Chemotherapy
Other Histological
Subtypes
All WT 270 9.2% 215 7.3% 2442 83.4%
WAGR 0 0.0% 1 5.0% 19 95.0%
GU 4 6.1% 5 7.6% 57 86.3%
DDS 9 * 37.5% * 0 0.0% 15 62.5%
BWS 0 0.0% 3 9.4% 29 90.6%
IHH 0 0.0% 5 * 17.2% * 24 82.8%
3.7. Tumor Volume
Tumor volume (TV) at diagnosis and after preoperative chemotherapie was available
in 1798 of 2927 (61.1%) patients (in 1698 patients without and in 91 with CPS or GU)
(Table 4). In children with WT and CPS or GU TV at diagnosis was significantly lower than
in patients without (349.4 mL vs. 487.5 mL; p < 0.001) (Table 4). Furthermore, with the
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exception of DDS a significant TV reduction can be achieved by preoperative chemotherapy
in WTs with CPS or GU with the largest effect of 86.9% in patients with BWS showing an
average TV after preoperative chemotherapy of only 38.3 mL (Table 4). In contrast, in DDS
no real change of TV under preoperative chemotherapy was observed (Table 4).
Table 4. Tumor volume (TV) at diagnosis and volume reduction achieved by preoperative (preop.) chemotherapy, * t-test:
p < 0.001 for lower initial TV in patients with CPS. TV is not available for all patients. Standard deviation (SD); CPS:
cancer predisposition syndrome; GU: Genitourinary malformations; BWS: Beckwith-Wiedemann spectrum; IHH: isolated
hemihypertrophy; DDS: Denys-Drash syndrome; WAGR: Wilms tumor, aniridia, genitourinary abnormalities, range of
developmental delays.
Mean Tumor Volume (TV) and [SD]
at Diagnosis after Preop. Chemo Volume Reduction
Patients without CPS or GU (N = 1698) 487.5 mL * [383.0] 228.0 mL [279.8] 259.5 mL [326.7] 53.2%
Patients with CPS or GU (N = 91) 349.4 mL * [381.7] 189.6 mL [255.7] 159.8 mL [315.3] 45.7%
WAGR (N = 10) 104.9 mL [179.0] 84.4 mL [156.8] 20.4 mL [90.1] 19.4%
GU (N = 32) 464.0 mL [329.3] 254.0 mL [213.2] 210.0 mL [281.2] 45.3%
DDS (N = 15) 379.3 mL [256.3] 380.7 mL [375.0] −1.4 mL [194.8] −0.4%
BWS (N = 17) 292.9 mL [539.1] 38.3 mL [54.2] 254.5 mL [514.3] 86.9%
IHH (N = 17) 307.7 mL [416.7] 112.7 mL [244.7] 195.0 mL [226.7] 63.4%
Patients with CPS or GU undergoing
surveillance (N = 11) 62.7 mL [112.0] 55.4 mL [142.9] 7.3 mL [36.9] 11.6%
Tumor volume at diagnosis in the 11 patients with CPS undergoing surveillance is
significantly smaller (TV in CPS patients with surveillance: mean 62.7 mL, median: 21.3 mL.
TV in CPS patients without surveillance: mean: 388.8 mL, median: 321.5 mL) (Figure 2).
Figure 2. TV at diagnosis of CPS patients as a function of CPS surveillance displayed as a boxplot. TV
at diagnosis of the 17 patients with CPS surveillance and of 101 patients without CPS surveillance. 2
outliers in patients with CPS surveillance at 160.0 mL and 396.0 mL and 3 outliers in patients without
CPS surveillance at 1631.0 mL, 1632.0 mL and 2051.0 mL. CPS patients with CPS surveillance show
significantly smaller TV at diagnosis (p < 0.001). “*”: outliers; CPS: cancer predisposition syndrome.
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3.8. Outcome
There was no statistically significant influence on EFS for the whole group of pa-
tients with a CPS (Figure 3A). However, patients with BWS showed a significantly worse
EFS (Figure 3B) and a higher relapse rate (34.4%) compared to other patients with WT
and/or nephroblastomatosis (13.7%). Out of 22 patients with BWS and only unilateral
disease at diagnosis 5 patients relapsed of whom 3 showed metachronic disease (3, 4.5
and 6 years after initial diagnosis). One of these 3 patients developed also lung and liver
metastasis and died 6 years after diagnosis. Of the other two relapsed patients one patient
developed a local relapse in the same kidney and the other one devloped lung metastasis
without local or metachronic relapse and both survived. Apart from these three patients,
metachronic disease occurred only in two further patients with CPS, one with WAGR
syndrom and one with IHH. The contralateral kidney tumors were diagnosed in these
patients 7 years (WAGR) and 10 months (IHH) after initial diagnosis, respectively. Further
analysis suggested that EFS tends to be worse in patients with nephroblastomatosis and a
syndrome than in patients without nephroblastomatosis (Figure 3C), particularly if they
had developed WT in addition (Figure 3D). Table S2 gives an overview of outcome data.
The only significant difference was seen in BWS for 5- and 10y EFS.
Figure 3. Event-free survival in different subgroups: (A) Influence of a syndrome on EFS in patients with WT and/or
nephroblastomatosis; Log Rank: p = 0.890; (B) Influence of BWS on EFS in patients with WT and/or nephroblastomatosis;
Log Rank: p = 0.002; (C) Influence of nephroblastomatosis on EFS in patients with a CPS; Log Rank: p = 0.086; (D) Influence
of WT on EFS in patients with nephroblastomatosis; Log Rank: p = 0.315. CPS: cancer predisposition syndrome; BWS:
Beckwith-Wiedemann spectrum; NBL: nephroblastomatosis, GU: Genitourinary malformations.
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In a multivariate analysis of all patients, nephroblastomatosis and bilaterality had a
significant influence on the risk of relapse and death. If only CPS and GU WT patients
were considered, such risk was only found for relapse but not for death (Table 5).
Table 5. Multivariate analysis in patients with a WT and/or nephroblastomatosis and only in patients with a syndrome;
*: p < 0.05. CPS: cancer predisposition syndrome.
WT and/or Nephroblastomatosis CPS Patients
Factor Relapse Death Relapse Death


















patients 0.594 0.931 83.2 0.139 1.422 88.1
bilaterality 0.000 1.579 * 73.4 0.030 1.976 * 88.2 0.003 3.013 * 65.4 0.639 1.861 85.6
nephro-
blastomatosis 0.005 1.220 72.1 0.074 0.266 * 96.2 0.032 1.264 73.3 0.167 0.225 96.7
4. Discussion
In our retrospective analysis we found that 5.8% of patients with WT and/or nephrob-
lastomatosis are associated with the top five syndromes (WAGR, BWS, DDS, IHH and GU)
in agreement with previous literature. With the exception of patients with GU and DDS,
female patients are more frequently affected. Patients with syndromes show smaller TVs
both at diagnosis and after preoperative chemotherapy, which might be due to the inclusion
in a screening program [20]. The statistically significant lower frequency of metastatic
disease at diagnosis in patients with a syndrome does not translates into a better EFS.
Therefore, other factors such as nephroblastomatosis and comorbidities must be considered
to explain their EFS, especially in patients with BWS. (Table 6).
Table 6. Summary of results in the top 5 syndromes associated with WT. * significant results (p < 0.05); ** isolated
nephroblastomatosis, Standard deviation (SD), Standard error (SE). BWS: Beckwith-Wiedemann spectrum; IHH: isolated

















WAGR 0.7 21.0 * [9.0] m < f NBL ** 30.0 * 19.4 % 87.5 {0.1} [9,21,22]
GU 2.3 33.0 [47.3] m > f * - 12.1 45.3 % 87.6 {0.4} [23]
DDS 0.8 16.0 * [12.2] m > f stromal type 29.2 * −0.4 % 94.7 {0.5} [24–27]
BWS 1.1 30.0 [29.7] m < f NBL ** 31.3 * 86.9 % 60.6 * {0.1} [28,29]





13.8 63.4 % 84.6 {0.1} [6,15,30,31]
4.1. Prevalence and Surveillance
The prevalence of syndromes in patients with WT is lower in our series compared to
the 8–17% in the literature [5,6]. This may be due to an underreporting in our retrospective
multicenter study where standardized reporting was carried out at diagnosis, hence early
in life with a probably incompletely symptomatology. BWS, for example, a syndrome with
variable features, is described with a prevalence of 1 up to 8% in other studies [12,18,29].
Therefore, not all patients with a WT CPS are included in ongoing ultrasound screening
programs. In our data the screening rate is depending on the clinical symptomatology and
highest in WAGR with 40% (Table 1). MacFarland et al. reported 12 patients diagnosed
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with BWS after a WT was already known [32]. This may explain our low prevalence of
1.1% and also undiagnosed BWS in other studies. Clinicians need to recognize subtle
manifestations of syndromes in WT patients to not overlook them. For clinical diagnosis of
BWS a new consensus statement has been published in this respect [33]. Knowledge about
specific associations between different syndromes and WT will allow an earlier diagnosis
of such WT, with CPSs demanding genetic testing, counselling and subsequently screening
programs. In this respect, it is important to separate clearly between the WT1 associated
CPS (DDS and WAGR) and the imprinting disorders (BWS and IHH) showing differences
in WT characteristics, e.g., age at diagnosis or the response to preoperative chemotherapy
as shown in our analysis.
4.2. Age at Diagnosis of WT/Nephroblastomatosis
Of all patients with syndromes, those with DDS are diagnosed the earliest followed
by WAGR [9]. Patients with GU and BWS also tend to be diagnosed earlier than those
without syndromes. The late median diagnosis at 45 months in IHH compared to other
syndromes suggests that IHH manifests itself clinically rather subtly [12,30] which is why
no surveillance for WT was carried out. Therefore, our results suggest that early age
at diagnosis of a WT without a syndrome should always raise awareness of a CPS. In
addition, in patients with the diagnosis of such a syndrome screening for WT needs to
start early and regularly up to the age when the manifestation of a WT becomes more
unlikely [20]. According to our data, for patients with DDS and WAGR such a screening
may stop already at the age of 4 or 5 years as also recommended by Hol et al. [8], whereas
in the other syndromic patients screening should continue at least up to the age of 7 years
as also consented for BWS [20] (Figure 1). In the work of Diller et al. the average age of
diagnosis of patients with GU was 13 months and thus significantly earlier compared to our
data (42.9 months). This difference in median age may be related to a different approach
as they analysed blood samples from 201 patients with a history of WT for constitutional
WT1 mutations, which was not carried out in our cohort of patients [34]. As a result of
their work, this underscores the need for a regular screening in patients with GU.
4.3. Tumor Volume and Response to Preoperative Chemotherapy
Tumor response to preoperative chemotherapy varies significantly between the differ-
ent syndromes and depends on the presence of a stromal subtype or WT1 mutation. Thus,
we confirm a poor response in patients with DDS [26,27]. These patients have comparably
larger initial TVs that can even increase after preoperative chemotherapy (Table 4). A
WT1 mutation/deletion path driven propensity for stromal components or even stromal
predominance is a likely reason [35,36]. The TV reduction after preoperative chemotherapy
is also poor in WAGR patients with WT1 deletion despite of missing stromal type WT
(Table 4). In contrast, an excellent response on preoperative chemotherapy is achieved
in patients with BWS. As a consequence of a poor TV reduction, a stromal subtype or
WT1 aberrations with an underlying syndrome may be possible. This is especially true for
patients with bilateral disease.
4.4. Bilaterality
The significantly increased frequency of bilaterality in patients with WAGR, GU,
DDS is consistent with previous work [9,23,24]. In patients with BWS we found a higher
percentage of bilaterality (31.3%) than Breslow et al. (21%) [9]. Consequently, patients with
unilateral disease and WAGR, DDS or BWS should always be regarded as predisposed for
bilaterality [4] and in cases of bilateral disease these three syndromes need to be kept in
mind, if not diagnosed yet.
4.5. Metastatic Disease
Metastases are a significantly less frequent event in patients with syndromes as com-
pared to non-syndromic WT. This may be due to an early diagnosis of WT or nephrob-
Cancers 2021, 13, 5016 10 of 12
lastomatosis in patients with syndromes and underscores the importance of a screening
program [20].
4.6. Histology
The majority of patients with syndromes have intermediate-risk WT. As described
earlier, patients with DDS are significantly more often affected by WT with a stromal
subtype and never with high risk tumors [24,25]. There is a significant association with
blastemal subtype after preoperative chemotherapy in patients with IHH and a trend in
BWS due to the frequently IGF2 driven biology. In contrast to the work of Green et al.,
focal and diffuse anaplasia do not occur as first histology in our data [30]. However after
nephroblastomatosis the development of diffuse anaplasia in case of a secondary WT is a
relatively frequent event [37]. We confirm the association between WAGR, BWS and IHH
and nephroblastomatosis found by others [9,21,31,33] in contrast to patients with DDS and
GU [23]. As nephroblastomatosis is found more often in patients with the above mentioned
three syndromes this raises the question whether all patients with nephroblastomatosis
need to be examined for CPS if not yet known [33].
4.7. Outcome
With the exception of patients with BWS showing a significantly worse EFS and in-
creased risk of relapse, CPS or GU in general have no impact on EFS. Breslow et al. found
no difference in WT with BWS neither in OS nor in EFS [9]. However, if nephroblastomato-
sis is present in our data, EFS tends to be worse, especially if these patients develop a WT as
already shown by Furtwängler et al. [37,38]. Therefore, patients with nephroblastomatosis
independent of a predisposition syndrome must be followed in regular intervals after the
end of treatment for longer periods of time to diagnose a relapse early in order to keep
their overall survival as high as for other patients [39].
5. Conclusions
Diagnosis of WT at an early age, bilateral tumors or nephroblastomatosis in patients
without a known CPS should always raise suspicion of an underlying CPS and genetic
testing and counselling should be offered to these patients and families. Screening for WT in
patients with a syndrome may stop earlier after the age of 4 to 5 years in patients with DDS
and WAGR as also recommended by Hol et al. [8], whereas for the other syndromes this
should last up to the age of 7 years and needs to continue in cases of nephroblastomatosis
even in CR after the end of first line treatment.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
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